FDA approves Retatrutide this year?
1 markets drugGLPEli LillyScience
About
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a ful…
Markets in this event
FDA approves Retatrutide this year? 11% chance
